Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 7/20 | 0.50 |
| ▸ | CTSS | P25774 | 6/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | PPARA | Q07869 | 7/20 | 0.47 |
| ▸ | PPARG | P37231 | 6/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | PPARD | Q03181 | 2/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2781378 | 1.00 | CTSK (0.50) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL205237 | 1.00 | CTSK (0.50) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL11276177 | 0.98 | CTSK (0.49) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL13571115 | 0.98 | CTSK (0.49) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL7306871 | 0.98 | CTSK (0.49) | CTSKCTSSMEN1GAAKMT2A | |
| Propylene Glycol SCHEMBL7982009 | 0.92 | CTSK (0.45) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL3873210 | 0.91 | CTSK (0.47) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL5285944 | 0.90 | CTSK (0.52) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL4711467 | 0.90 | CTSK (0.52) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL4024795 | 0.90 | CTSK (0.52) | CTSKCTSSMEN1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 298 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117106189-A | Metal organic framework artificial hydrolase and preparation method and application thereof | 华南理工大学 | 2023-11-24 | — | — | CN | claimed |
| EP-4711368-A1 | AZEPINE COMPOUND, AND COMPOSITION AND USE THEREOF | CHENGDU MFS PHARMA. CO., LTD. (CN) | 2026-03-18 | — | — | EP | disclosed |
| EP-4688789-A1 | MACROCYCLIC RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20260001889-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS INC (US) | 2026-01-01 | — | — | US | disclosed |
| US-12497392-B2 | EP300/CBP inhibitor | HINOVA PHARMACEUTICALS INC. (CN) | 2025-12-16 | — | — | US | disclosed |
| EP-4658667-A1 | CYCLIC PEPTIDES FOR INHIBITING TNF RECEPTOR 1 ACTIVITY | Merck Sharp & Dohme LLC (US) | 2025-12-10 | — | — | EP | disclosed |
| EP-4622991-A2 | SYNTHESIS OF A CYCLIC PEPTIDE | Janssen Pharmaceutica NV (BE) | 2025-10-01 | — | — | EP | disclosed |
| US-12384797-B2 | Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia | PTC THERAPEUTICS, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| US-12358951-B2 | Cyclic peptide antibiotics | GENENTECH, INC. (US) | 2025-07-15 | — | — | US | disclosed |
| CN-115335373-B | Compounds and uses thereof | 福宏治疗公司 | 2025-05-20 | — | — | CN | disclosed |
| US-5506356-A | RENIN INHIBITORS; HYPOTENSIVE AGENTS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1996-04-09 | — | — | US | disclosed |
| US-5481036-A | RENIN INHIBITORS, HYPOTENSIVE AGENTS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1996-01-02 | — | — | US | disclosed |
| CN-1098408-A | The heterocycle inhibitor of farnesyl-protein transferase | BRISTOL MYERS SQIBB COMPANY (US) | 1995-02-08 | — | — | CN | disclosed |
| EP-0618221-A2 | Heterocyclic inhibitors of farnesyl protein transferase | BRISTOL-MYERS SQUIBB COMPANY (US) | 1994-10-05 | — | — | EP | disclosed |
| US-5319082-A | N-acylamino acid derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1994-06-07 | — | — | US | disclosed |
| US-5240924-A | Dipeptide hypotensives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1993-08-31 | — | — | US | disclosed |
| WO-1992014706-A1 | CYCLOPENTANE-DERIVED GLUTARAMIDE ANTIHYPERTENSIVE AGENTS | PFIZER LIMITED (GB) | 1992-09-03 | — | — | WO | disclosed |
| US-5122523-A | Hypotensive agents | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1992-06-16 | — | — | US | disclosed |
| CN-1032786-A | N-acyl amino acid derivative and uses thereof | BANYU PHARMA CO LTD (JP) | 1989-05-10 | — | — | CN | disclosed |
| EP-0309766-A2 | N-acylamino acid derivatives and their use | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1989-04-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001889-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | SF3B1, SF3A1, SF3B5 | CTSK 4670/4885CTSS 4634/4885MEN1 4113/4885 |
| US-12497392-B2 | EP300/CBP inhibitor | EP300, MLLT1, CREBBP | CTSK 3493/4885CTSS 3589/4885MEN1 1021/4885 |
| US-12358951-B2 | Cyclic peptide antibiotics | NPPA, LNPEP, CLPP | CTSK 619/4885CTSS 738/4885MEN1 4359/4885 |
| US-12384797-B2 | Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia | SF3B5, SF3B2, SF3B1 | CTSK 4597/4885CTSS 4459/4885MEN1 1230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.